Table 2.
Females |
Model 1 for males (matched to females by age and Nglom) |
Model 2 for males (matched to females by age, Nglom and BSA) |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) |
Nglom (million) |
HTN (proportion; %) |
Rx HTN (proportion; %) |
Age (years) |
Nglom (million) |
HTN (proportion; %) |
Rx HTN (proportion; %) |
Age (years) |
Nglom (million) |
HTN (proportion; %) |
Rx HTN (proportion; %) |
||
African Americans (n = 32) | High Nglom | 38 | 1.16 | 0/6; 0% | 0/0; 0% | 37.0NS | 1.18NS | 2/6; 33% | 2/6; 33% | 30.5NS | 1.17NS | 2/6; 33% | 2/6; 33% |
(28–49) | (1.1–1.3) | NA | NA | (27–43) | (1.1–1.3) | NA | NA | (21–43) | (1.1–1.3) | NA | NA | ||
Low Nglom | 38.5 | 0.59 | 4/6; 67% | 3/6; 50% | 39.0NS | 0.59NS | 4/6; 67% | 3/6; 50% | 40.0NS | 0.53NS | 4/6; 67% | 2/6; 33% | |
(28–50) | (0.5–0.6) | NA | NA | (35–53) | (0.5–0.6) | NA | NA | (34–54) | (0.5–0.6) | NA | NA | ||
Caucasian Americans (n = 34) | High Nglom | 45.5 | 1.1 | 0/6; 0% | 0/0; 0% | 44.0NS | 1.11NS | 1/6; 17% | 1/6; 17% | 47.5NS | 1.04NS | 1/6; 17% | 1/6; 17% |
(38–50) | (1.1–1.2) | NA | NA | (39–59) | (0.9–1.2) | NA | NA | (38–61) | (0.9–1.2) | NA | NA | ||
Low Nglom | 46.5 | 0.46 | 2/6; 33% | 1/6; 17% | 40.5NS | 0.56NS | 3/6; 50% | 1/6; 17% | 51.5NS | 0.58NS | 3/6; 50% | 3/6; 50% | |
(39–55) | (0.4–0.5) | NA | NA | (37–48) | (0.3–0.6) | NA | NA | (39–57) | (0.4–0.6) | NA | NA |
Values for age and Nglom are expressed as median (inter quartile range). HTN (HTN: hypertensive status) is expressed as a proportion and percentage of hypertensive subjects; Rx HTN (history of prescribed anti-hypertensive medication), which is expressed as a proportion and percentage of subjects receiving anti-hypertensive therapy to control blood pressure; Nglom: total nephron number; NSP > 0.05; all statistical comparisons were performed between females and model 1 for males and between females and model 2 for males; NA, not applicable.